This was after waiting an average of 95 mo. and excellent outcomes with the addition of rituximab (anti-B cell) have been achieved. Bortezomib (anti-plasma cell) and eculizumab (match inhibition) may be NCH 51 good adjuncts for patients who are broadly sensitized with strong, complement-fixing HLA antibodies. Excellent outcomes have been achieved in ABO incompatible transplantation with the combination of antibody removal, B cell depletion, and pre-transplant immunosuppression. Kidney paired donation has emerged as a reasonable alternative for programs who cannot provide desensitization or in conjunction with desensitization. INTRODUCTION Kidney transplantation is the platinum standard for treating end-stage kidney disease and amazing strides have been made over the last thirty years. However, there are now over 100000 people awaiting kidney transplantation in the United States according to the Organ Procurement and Transplantation Network. A significant proportion of these patients are broadly human-leukocyte antigen (HLA) sensitized and will have to wait longer to find an acceptable match; some may by no means. There are also those around the wait list with living donors who NCH 51 are blood type incompatible (ABOi), but would normally be an acceptable match. The long wait times incurred lead to increased mortality around the kidney transplant list[1]. The ability to provide a blood type or HLA incompatible transplant decreases mortality and gives hope to those languishing around the wait list. Desensitization therapies started to emerge in the 1980s. Donor specific blood transfusions were performed for HLA desensitization with limited success. There was more success with ABOi transplantation during this time period with techniques employing a combination of plasma exchange (PLEX) and splenectomy. HLA antibody desensitization with intravenous immunoglobulin (IVIG) was first reported in the mid-1990s and ushered in a new era of transplantation. New immunomodulatory NCH 51 therapies have since emerged that successfully allow HLA and blood type incompatible transplant. In this review, we will discuss the current methods and future directions of desensitization therapies. IVIG AND RITUXIMAB (ANTI-B CELL) IVIG is usually a complex preparation derived from the gamma globulin portion of pooled human plasma used to treat primary hypogammaglobulinemia, acquired antibody deficiency, and various autoimmune Rabbit polyclonal to Aquaporin2 disorders. It modulates the auto- and allo-immune response broad-acting mechanisms. These mechanisms NCH 51 include neutralization of circulating antibodies, inhibition of B and T cell proliferation interactions with Fc receptors, alteration of cytokine production, and down-regulation of match. It therefore has powerful immunomodulatory effects and is now widely used for NCH 51 desensitization and treatment of antibody-mediated rejection (ABMR). The efficacy of high-dose IVIG (1-2 g/kg per dose) was initially described separately by Glotz et al[2] and Tyan et al[3]. IVIG was administered on a monthly basis to those awaiting either a living or deceased donor kidney transplant. An improvement in panel reactive antibodies (PRA) and transplant rates was observed. These early successes lead to the first randomized, multicenter, placebo-controlled trial for desensitization. The National Institute of Health Ig02 trial included a total of 101 highly sensitized patients with a PRA greater than 50%. Subjects were randomized to receive dialysis with IVIG (2 g/kg) monthly for 4 mo or dialysis with comparative volume of placebo[4] (Physique ?(Figure1).1). Patients receiving high-dose IVIG experienced a statistically significant reduction in.